Myriam D.
- Country
- France
- Department
- Service de Néphrologie adulte
Research Overview
- Long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy: an open-label extension study
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Povetacicept in Adults with Immunoglobulin A Nephropathy
- Efficacy and Safety Evaluation of Frexalimab, SAR442970, and Rilzabrutinib in Primary Focal Segmental Glomerulosclerosis and Minimal Change Disease
Data & Insights
Has run more than one trial at 39 of 149 partner sites.
Specializations
Glomerular Disorders
This investigator specializes in treating complex glomerular diseases, with particular emphasis on focal segmental glomerulosclerosis (FSGS) and minimal change disease. Their research explores innovative therapeutic approaches for managing these conditions.
- Primary FSGS management
- Proteinuria reduction strategies
- Novel therapeutic agents
Their work includes evaluation of targeted therapies for patients with treatment-resistant glomerular conditions.
Immune-Mediated Nephropathies
The investigator focuses on treating immune system diseases affecting the kidneys, particularly IgA Nephropathy. Their research encompasses innovative approaches to managing immune-mediated kidney disorders.
- IgA Nephropathy treatment
- Immune system modulation
- Renal function preservation
Their expertise extends to evaluating novel compounds for treating immunological kidney conditions.
Therapeutic Innovation
The investigator studies advanced therapeutic options for kidney diseases, focusing on novel compounds and their applications in treating various renal conditions.
- Experimental therapeutics
- Clinical efficacy assessment
- Long-term treatment outcomes
Their research involves evaluating both established and emerging treatments for kidney disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.